Latest On Navidea Biopharmaceuticals, Inc (NAVB):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 22:39 EST | News | Navidea promotes Michael Sherman Blue to CMO post | N/A |  |
| 2023-03-31 08:01 EST | News | Navidea chief medical officer steps down; hires G2G Ventures as consultants | N/A | |
| 2023-03-21 23:11 EST | News | Navidea Biopharm GAAP EPS of -$0.11 | N/A | |
| 2023-03-21 23:11 EST | News | Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-01-03 18:46 EST | News | Navidea stock soars ~25% on upcoming US patent linked to cancer drug pipeline | N/A | |
| 2022-11-15 22:32 EST | News | Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-14 12:21 EST | News | Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.08M | N/A | |
| 2022-11-14 12:21 EST | News | Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.07M | N/A | |
| 2022-09-09 08:06 EST | News | Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2022 Earnings Call Transcript | N/A | |
| 2022-08-15 19:07 EST | News | Navidea Biopharm GAAP EPS of -$0.10, revenue of $0.06M | N/A | |
| 2022-07-05 17:05 EST | News | Navidea biopharmaceuticals secures additional bridge loan funding of 1M | N/A | |
| 2022-05-13 22:57 EST | News | Navidea Biopharmaceuticals, Inc. (NAVB) Management on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-12 21:22 EST | News | Navidea Biopharm GAAP EPS of -$0.10 | N/A | |
| 2022-04-20 16:29 EST | News | Navidea reports initial data from phase 2b study of imaging agent in rheumatoid arthritis patients | N/A | |
| 2022-04-19 08:49 EST | News | Navidea stock soars ~20%, to get patents in US, Japan | N/A | |
| 2022-04-18 18:23 EST | News | Navidea Biopharma rises 16% on Indian approval for Lymphoaim | N/A | |
| 2022-04-13 05:39 EST | News | Navidea receives NYSE American acceptance letter; secures $2.5M bridge loan | N/A | |
| 2022-03-24 18:31 EST | News | Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-24 18:30 EST | News | Navidea stock falls 13% after dismal Q4 results | N/A | |
| 2022-03-23 08:00 EST | News | Navidea Biopharm GAAP EPS of -$0.12, revenue of $0.05M | N/A | |
| 2022-02-08 03:02 EST | News | Navidea in research pact to evaluate Tc99m tilmanocept as a prognostic marker | N/A | |
| 2022-02-04 07:40 EST | News | Navidea gets notice on listing noncompliance; settles Platinum lawsuit | N/A | |
| 2021-12-16 10:50 EST | News | Navidea Biopharma ends stock purchase agreement | N/A | |
| 2021-11-26 21:13 EST | News | Warning: NAVB is at high risk of performing badly | N/A | |
| 2021-11-11 10:05 EST | News | Navidea Biopharm EPS beats by $0.03 | N/A | |
| 2021-11-11 10:05 EST | News | Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-10 12:36 EST | News | Navidea Biopharm Q3 2021 Earnings Preview | N/A | |
| 2021-10-26 23:36 EST | News | Navidea Biopharmaceuticals CEO-CFO Jed Latkin resigns | N/A | |
| 2021-10-26 23:36 EST | News | Navidea Biopharmaceuticals CEO Jed Latkin resigns | N/A | |
| 2021-08-12 00:55 EST | News | Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-21 16:25 EST | News | AcelRx Pharmaceuticals, GBS leads healthcare gainers; Allied Healthcare Products, Allena Pharmaceuticals among | N/A | |
| 2021-07-21 16:25 EST | News | Navidea shares surge on regulatory update for rheumatoid arthritis trial | N/A | |
| 2021-07-21 16:24 EST | News | Navidea provides enrollment update in mid-stage rheumatoid arthritis trial | N/A | |
| 2021-03-25 18:03 EST | News | Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-24 22:15 EST | News | Navidea Biopharm EPS beats by $0.01, misses on revenue | N/A | |
| 2021-03-02 16:28 EST | News | Navidea Biopharmaceuticals launches $5M private placement with existing investor | N/A | |
| 2021-02-10 15:35 EST | News | Navidea submits formal Type B Meeting Request to FDA | N/A | |
| 2021-01-06 16:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 20:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 20:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 04:48 EST | News | Navidea Biopharm EPS misses by $0.04, beats on revenue | N/A | |
| 2020-11-13 04:48 EST | News | Navidea imaging agent shows predictive value in rheumatoid arthritis | N/A | |
| 2020-11-13 04:47 EST | News | Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-07 16:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-10 09:10 EST | News | Navidea Biopharma's lead asset data to be presented in an upcoming Rheumatology meet | N/A | |
| 2020-09-26 13:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 05:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-15 21:01 EST | News | Navidea Biopharmaceuticals: Too Many Risks Involved | N/A | |
| 2020-09-02 21:53 EST | Insider Trade | John K Jr. Scott has directly acquired 5,000 shares and currently holds 8,047,162 shares. | Buy | |
| 2020-08-25 01:21 EST | Analyst Rating | The Analyst Target Price has increased from $6.5 to $7.5. | Buy | |
About Navidea Biopharmaceuticals, Inc (NAVB):
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a collaboration agreement with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
General
- Name Navidea Biopharmaceuticals, Inc
- Symbol NAVB
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 13
- Last Split Factor1:20
- Last Split Date2019-04-26
- Fiscal Year EndDecember
- IPO Date1992-11-10
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.navidea.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 59.6
- Price/Book (Most Recent Quarter) 4.36
- Enterprise Value Revenue 55.87
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.11
- Operating Margin -1311%
- Return on Assets -123%
- Return on Equity -2640%
- Revenue 815061
- Earnings Per Share -$1.24
- Revenue Per Share $0.04
- Gross Profit 651159
- Quarterly Earnings Growth 13.3%
View More
Highlights
- Market Capitalization 64.36 million
- EBITDA -9780315
- PE Ratio -0.51
- Analyst Target Price $7.5
- Book Value Per Share $0.54
View More
Share Statistics
- Shares Outstanding 27.98 million
- Shares Float 18.71 million
- % Held by Insiders 3090%
- % Held by Institutions 6.02%
- Shares Short 189238
- Shares Short Prior Month 248123
- Short Ratio 0.35
- Short % of Float 1%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 1.82
- 52 Week High $5.36
- 52 Week Low $0.63
- 50 Day Moving Average 2.44
- 200 Day Moving Average 2.45
View More
Dividends
- Dividend Date 2019-04-26
- ExDividend Date N/A
- Dividend Yield 0%
View More
Navidea Biopharmaceuticals, Inc (NAVB) Dividend Calendar:
NAVB's last dividend payment was made to shareholders on April 26, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Navidea Biopharmaceuticals, Inc (NAVB) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-12 | $N/A | -$0.13 | -$0.09 | -44.44% |
| 2020-06-30 | 2020-08-13 | $N/A | -$0.11 | -$0.10 | -10% |
| 2020-03-31 | 2020-05-15 | $156272 | -$0.13 | -$0.13 | 0% |
| 2019-12-31 | 2020-03-11 | $119299 | -$0.15 | -$0.15 | -3.45% |
| 2019-09-30 | 2019-11-07 | $236811 | -$0.17 | -$0.17 | 0% |
| 2019-06-30 | 2019-08-08 | $260092 | -$0.24 | -$0.15 | -60% |
| 2019-03-31 | 2019-05-08 | $136032 | -$0.24 | ||
| 2018-12-31 | 2019-03-07 | $119321 | -$0.33 | ||
| 2018-09-30 | 2018-11-07 | $231458 | -$0.46 | ||
| 2018-06-30 | 2018-08-08 | $542127 | -$0.29 | ||
| 2018-03-31 | 2018-05-08 | $276445 | -$0.83 | ||
| 2017-12-31 | 2018-03-08 | $2.66 million | -$0.50 | ||
| 2017-09-30 | 2017-11-07 | $369546 | -$0.17 | ||
| 2017-06-30 | 2017-08-08 | $-1341779 | -$0.64 | ||
| 2017-03-31 | 2017-05-10 | $89.28 million | $10.38 | ||
| 2016-12-31 | 2017-03-29 | $3.36 million | -$0.50 | ||
| 2016-09-30 | 2016-11-03 | $8.5 million | -$0.01 | ||
| 2016-06-30 | 2016-08-04 | $5.39 million | -$0.80 | -$0.60 | -33.33% |
| 2016-03-31 | 2016-05-17 | $4.72 million | -$0.40 | -$0.60 | 33.33% |
| 2015-12-31 | 2016-03-15 | $4.29 million | -$0.40 | -$0.60 | 33.33% |
| 2015-09-30 | 2015-11-04 | $3.98 million | -$0.05 | -$0.04 | -25% |
| 2015-06-30 | 2015-07-30 | $2.87 million | -$0.06 | -$0.04 | -50% |
| 2015-03-31 | 2015-05-11 | $2.11 million | -$0.05 | -$0.03 | -66.67% |
| 2014-12-31 | 2015-03-05 | $2.2 million | -$0.05 | -$0.05 | 0% |
| 2014-09-30 | 2014-11-06 | $2.25 million | -$0.05 | -$0.06 | 16.67% |
| 2014-06-30 | 2014-08-06 | $1.08 million | -$1.40 | -$1.35 | -3.7% |
| 2014-03-31 | 2014-05-07 | $752000 | -$1.20 | -$1.90 | 36.84% |
| 2013-12-31 | 2014-03-06 | $534000 | -$2.00 | -$1.60 | -25% |
| 2013-09-30 | 2013-11-06 | $401000 | -$1.80 | -$1.64 | -9.76% |
| 2013-06-30 | 2013-08-07 | $195000 | -$1.80 | -$1.30 | -38.46% |
| 2013-03-31 | 2013-05-08 | $N/A | -$1.20 | -$1.33 | 9.77% |
| 2012-12-31 | 2013-03-06 | $7000 | -$1.40 | -$1.60 | 12.5% |
| 2012-09-30 | 2012-11-08 | $-60000 | -$1.80 | -$1.20 | -50% |
| 2012-06-30 | 2012-08-06 | $60000 | -$1.20 | -$1.24 | 3.23% |
| 2012-03-31 | 2012-05-02 | $12000 | -$1.40 | -$1.25 | -12% |
| 2011-12-31 | 2012-02-29 | $342000 | -$1.60 | -$1.04 | -53.85% |
| 2011-09-30 | 2011-10-26 | $20.36 million | -$1.40 | $2.40 | -158.33% |
| 2011-06-30 | 2011-07-27 | $3.2 million | -$0.40 | -$0.50 | 20% |
| 2011-03-31 | 2011-05-09 | $336000 | -$1.00 | -$0.44 | -127.27% |
| 2010-12-31 | 2011-03-07 | $467000 | -$0.60 | -$0.50 | -20% |
| 2010-09-30 | 2010-11-10 | $150000 | -$0.60 | -$0.20 | -200% |
| 2010-06-30 | 2010-08-09 | $N/A | -$12.80 | -$0.40 | -3100% |
| 2010-03-31 | 2010-04-28 | $N/A | -$0.60 | -$0.20 | -200% |
| 2009-12-31 | 2010-03-03 | $2.45 million | -$0.09 | -$0.30 | 70.07% |
| 2009-09-30 | 2009-11-02 | $2.59 million | -$6.80 | -$6.20 | -9.68% |
| 2009-06-30 | 2009-08-11 | $1.8 million | -$4.20 | -$0.40 | -950% |
| 2009-03-31 | 2009-05-07 | $2.68 million | $0.17 | ||
| 2008-12-31 | 2009-03-11 | $1.96 million | -$0.35 | ||
| 2008-09-30 | 2008-11-05 | $1.72 million | -$0.60 | -$0.40 | -50% |
| 2008-06-30 | 2008-08-04 | $2.13 million | -$0.20 | -$0.60 | 66.67% |
| 2008-03-31 | 2008-05-01 | $1.78 million | -$0.40 | -$0.20 | -100% |
| 2007-12-31 | 2008-03-19 | $1.88 million | -$0.60 | -$0.20 | -200% |
| 2007-09-30 | 2007-10-30 | $1.99 million | -$0.20 | -$0.40 | 50% |
| 2007-06-30 | 2007-07-26 | $1.52 million | -$0.40 | -$0.40 | 0% |
| 2007-03-31 | 2007-04-30 | $1.74 million | -$0.40 | -$0.40 | 0% |
| 2006-12-31 | 2007-03-08 | $1.87 million | -$0.44 | ||
| 2006-09-30 | 2006-11-02 | $958000 | -$0.60 | -$0.60 | 0% |
| 2006-06-30 | 2006-08-02 | $1.43 million | -$0.20 | -$0.40 | 50% |
| 2006-03-31 | 2006-05-01 | $1.79 million | -$0.40 | -$0.40 | 0% |
| 2005-12-31 | 2006-03-06 | $1.42 million | -$0.40 | -$0.80 | 50% |
| 2005-09-30 | 2005-11-03 | $1.33 million | -$0.40 | -$0.60 | 33.33% |
| 2005-06-30 | 2005-08-01 | $1.7 million | -$0.40 | -$0.60 | 33.33% |
| 2005-03-31 | 2005-04-28 | $1.47 million | -$0.40 | -$0.20 | -100% |
| 2004-12-31 | 2005-02-15 | $1.25 million | -$0.79 | ||
| 2004-09-30 | 2004-11-10 | $1.73 million | -$0.08 | ||
| 2004-06-30 | 2004-08-10 | $1.55 million | -$0.15 | ||
| 2004-03-31 | 2004-05-12 | $1.43 million | -$0.22 | ||
| 2003-12-31 | 2004-02-24 | $1.9 million | -$0.25 | ||
| 2003-09-30 | 2003-11-10 | $1.19 million | -$0.34 | ||
| 2003-06-30 | 2003-08-10 | $1.89 million | -$0.04 | ||
| 2003-03-31 | 2003-05-28 | $1.54 million | -$0.25 | ||
| 2002-12-31 | 2003-02-26 | $1.68 million | -$0.09 | ||
| 2002-09-30 | 2002-11-27 | $919000 | -$0.60 | ||
| 2002-06-30 | 2002-08-28 | $1.27 million | -$0.48 | ||
| 2002-03-31 | 2002-03-31 | $1.06 million | -$0.47 | ||
| 2001-12-31 | 2001-12-31 | $2.12 million | -$0.40 | ||
| 2001-09-30 | 2001-09-30 | $1.92 million | $0.31 | ||
| 2001-06-30 | 2001-06-30 | $2.4 million | $0.14 | ||
| 2001-03-31 | 2001-03-31 | $1.75 million | $0.06 | ||
| 2000-09-30 | 2000-09-30 | $2.33 million | $0.39 | ||
| 2000-06-30 | 2000-06-30 | $2.71 million | $0.48 | ||
| 2000-03-31 | 2000-03-31 | $1.86 million | -$0.62 | ||
| 1999-09-30 | 1999-09-30 | -$3.07 | |||
| 1999-06-30 | 1999-06-30 | -$1.28 | |||
| 1999-03-31 | 1999-03-31 | -$1.15 | |||
| 1998-09-30 | 1998-11-03 | -$4.80 | -$2.60 | -84.62% | |
| 1998-06-30 | 1998-08-04 | -$4.60 | -$3.80 | -21.05% | |
| 1998-03-31 | 1998-05-05 | -$6.20 | -$3.00 | -106.67% | |
| 1997-12-31 | 1998-02-18 | -$5.20 | -$4.50 | -15.56% | |
| 1997-09-30 | 1997-11-03 | -$4.80 | -$6.00 | 20% | |
| 1997-06-30 | 1997-07-31 | -$6.40 | -$4.67 | -37.05% | |
| 1997-03-31 | 1997-05-06 | -$4.20 | -$5.60 | 25% | |
| 1996-12-31 | 1997-02-28 | -$6.20 | -$3.90 | -58.97% | |
| 1996-09-30 | 1996-11-07 | -$4.20 | -$4.13 | -1.69% | |
| 1996-03-31 | 1996-05-03 | -$4.00 | -$4.20 | 4.76% | |
| 1995-12-31 | 1996-02-21 | -$3.80 | -$3.00 | -26.67% | |
| 1995-09-30 | 1995-11-06 | -$3.20 | -$3.40 | 5.88% | |
| 1995-06-30 | 1995-08-11 | -$3.60 | -$3.60 | 0% |
Navidea Biopharmaceuticals, Inc (NAVB) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Navidea Biopharmaceuticals, Inc (NAVB) Chart:
Navidea Biopharmaceuticals, Inc (NAVB) News:
Below you will find a list of latest news for Navidea Biopharmaceuticals, Inc (NAVB) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Navidea Biopharmaceuticals, Inc (NAVB) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest NAVB Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 5:26 PM EST | 2 | $0.85 |
| Jun 13, 2022 5:28 PM EST | 3 | $0.85 |
| Jun 13, 2022 5:28 PM EST | 3 | $0.85 |
| Jun 13, 2022 6:26 PM EST | 3 | $0.8999 |
| Jun 13, 2022 7:22 PM EST | 11 | $0.82 |
Navidea Biopharmaceuticals, Inc (NAVB) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-24 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/810509/000143774920013727/0001437749-20-013727-index.htm |
| 2020-01-06 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/810509/000000000020000094/0000000000-20-000094-index.htm |
| 2020-06-16 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/810509/000000000020005327/0000000000-20-005327-index.htm |
| 2020-09-01 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/810509/000000000020008239/0000000000-20-008239-index.htm |
| 2019-06-24 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/810509/000091957419004277/0000919574-19-004277-index.htm |
| 2018-09-24 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/810509/000119312518281390/0001193125-18-281390-index.htm |
| 2019-06-24 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/810509/000119312519180272/0001193125-19-180272-index.htm |
| 2019-12-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/810509/000119312519312785/0001193125-19-312785-index.htm |
| 2020-02-26 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/810509/000119312520050131/0001193125-20-050131-index.htm |
| 2020-09-02 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/810509/000119312520238219/0001193125-20-238219-index.htm |
| 2017-12-22 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/810509/000143774917021129/0001437749-17-021129-index.htm |
| 2017-12-27 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/810509/000143774917021164/0001437749-17-021164-index.htm |
| 2018-02-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918003132/0001437749-18-003132-index.htm |
| 2018-02-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918003134/0001437749-18-003134-index.htm |
| 2018-02-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918003137/0001437749-18-003137-index.htm |
| 2018-02-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918003139/0001437749-18-003139-index.htm |
| 2018-02-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918003184/0001437749-18-003184-index.htm |
| 2018-03-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918004218/0001437749-18-004218-index.htm |
| 2018-03-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918004650/0001437749-18-004650-index.htm |
| 2018-03-15 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/810509/000143774918004756/0001437749-18-004756-index.htm |
| 2018-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918004830/0001437749-18-004830-index.htm |
| 2018-04-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918006076/0001437749-18-006076-index.htm |
| 2018-04-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918006324/0001437749-18-006324-index.htm |
| 2018-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918009054/0001437749-18-009054-index.htm |
| 2018-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/810509/000143774918009223/0001437749-18-009223-index.htm |
| 2018-05-31 | SD | https://www.sec.gov/Archives/edgar/data/810509/000143774918010994/0001437749-18-010994-index.htm | |
| 2018-06-07 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/810509/000143774918011441/0001437749-18-011441-index.htm |
| 2018-07-09 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/810509/000143774918013138/0001437749-18-013138-index.htm |
| 2018-07-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918013286/0001437749-18-013286-index.htm |
| 2018-07-20 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/810509/000143774918013527/0001437749-18-013527-index.htm |
| 2018-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/810509/000143774918014956/0001437749-18-014956-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918015009/0001437749-18-015009-index.htm |
| 2018-08-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918015682/0001437749-18-015682-index.htm |
| 2018-08-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918015733/0001437749-18-015733-index.htm |
| 2018-08-16 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/810509/000143774918015735/0001437749-18-015735-index.htm |
| 2018-08-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918015739/0001437749-18-015739-index.htm |
| 2018-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918015945/0001437749-18-015945-index.htm |
| 2018-09-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918017131/0001437749-18-017131-index.htm |
| 2018-10-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918018026/0001437749-18-018026-index.htm |
| 2018-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918018057/0001437749-18-018057-index.htm |
| 2018-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918019062/0001437749-18-019062-index.htm |
| 2018-11-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918019365/0001437749-18-019365-index.htm |
| 2018-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918019852/0001437749-18-019852-index.htm |
| 2018-11-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/810509/000143774918020274/0001437749-18-020274-index.htm |
| 2018-11-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918021350/0001437749-18-021350-index.htm |
| 2018-11-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774918021404/0001437749-18-021404-index.htm |
| 2018-12-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918021874/0001437749-18-021874-index.htm |
| 2018-12-12 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918021926/0001437749-18-021926-index.htm |
| 2018-12-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774918022256/0001437749-18-022256-index.htm |
| 2018-12-21 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/810509/000143774918022458/0001437749-18-022458-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919000184/0001437749-19-000184-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919000186/0001437749-19-000186-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919000188/0001437749-19-000188-index.htm |
| 2019-02-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919001640/0001437749-19-001640-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919002255/0001437749-19-002255-index.htm |
| 2019-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919002329/0001437749-19-002329-index.htm |
| 2019-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919002331/0001437749-19-002331-index.htm |
| 2019-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919002338/0001437749-19-002338-index.htm |
| 2019-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919002350/0001437749-19-002350-index.htm |
| 2019-02-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919003001/0001437749-19-003001-index.htm |
| 2019-03-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919004334/0001437749-19-004334-index.htm |
| 2019-03-15 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/810509/000143774919005086/0001437749-19-005086-index.htm |
| 2019-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919005549/0001437749-19-005549-index.htm |
| 2019-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919006744/0001437749-19-006744-index.htm |
| 2019-04-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919007613/0001437749-19-007613-index.htm |
| 2019-04-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919008036/0001437749-19-008036-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/810509/000143774919009295/0001437749-19-009295-index.htm |
| 2019-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919010054/0001437749-19-010054-index.htm |
| 2019-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919010057/0001437749-19-010057-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919010383/0001437749-19-010383-index.htm |
| 2019-05-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919010580/0001437749-19-010580-index.htm |
| 2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774919011608/0001437749-19-011608-index.htm |
| 2019-06-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/810509/000143774919011990/0001437749-19-011990-index.htm |
| 2019-06-17 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/810509/000143774919012156/0001437749-19-012156-index.htm |
| 2019-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919012157/0001437749-19-012157-index.htm |
| 2019-06-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/810509/000143774919012987/0001437749-19-012987-index.htm |
| 2019-06-28 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/810509/000143774919012988/0001437749-19-012988-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919016046/0001437749-19-016046-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/810509/000143774919016235/0001437749-19-016235-index.htm |
| 2019-08-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919016374/0001437749-19-016374-index.htm |
| 2019-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919020787/0001437749-19-020787-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919021964/0001437749-19-021964-index.htm |
| 2019-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/810509/000143774919022151/0001437749-19-022151-index.htm |
| 2019-12-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919023738/0001437749-19-023738-index.htm |
| 2019-12-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919024217/0001437749-19-024217-index.htm |
| 2019-12-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774919025009/0001437749-19-025009-index.htm |
| 2019-12-31 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/810509/000143774919025046/0001437749-19-025046-index.htm |
| 2020-01-07 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/810509/000143774920000263/0001437749-20-000263-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920002027/0001437749-20-002027-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920002030/0001437749-20-002030-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920002034/0001437749-20-002034-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920002036/0001437749-20-002036-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920002040/0001437749-20-002040-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920002042/0001437749-20-002042-index.htm |
| 2020-02-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920002715/0001437749-20-002715-index.htm |
| 2020-02-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/810509/000143774920002937/0001437749-20-002937-index.htm |
| 2020-02-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920002938/0001437749-20-002938-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920003172/0001437749-20-003172-index.htm |
| 2020-03-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920004804/0001437749-20-004804-index.htm |
| 2020-03-18 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/810509/000143774920005567/0001437749-20-005567-index.htm |
| 2020-05-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920010444/0001437749-20-010444-index.htm |
| 2020-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920010756/0001437749-20-010756-index.htm |
| 2020-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/810509/000143774920010995/0001437749-20-010995-index.htm |
| 2020-05-18 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/810509/000143774920011059/0001437749-20-011059-index.htm |
| 2020-05-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920011590/0001437749-20-011590-index.htm |
| 2020-06-03 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/810509/000143774920012350/0001437749-20-012350-index.htm |
| 2020-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920012478/0001437749-20-012478-index.htm |
| 2020-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920012480/0001437749-20-012480-index.htm |
| 2020-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920012481/0001437749-20-012481-index.htm |
| 2020-06-17 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/810509/000143774920013341/0001437749-20-013341-index.htm |
| 2020-06-17 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/810509/000143774920013343/0001437749-20-013343-index.htm |
| 2020-06-22 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/810509/000143774920013535/0001437749-20-013535-index.htm |
| 2020-06-24 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/810509/000143774920013727/0001437749-20-013727-index.htm |
| 2020-07-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920016159/0001437749-20-016159-index.htm |
| 2020-07-31 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/810509/000143774920016160/0001437749-20-016160-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920017190/0001437749-20-017190-index.htm |
| 2020-08-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/810509/000143774920017535/0001437749-20-017535-index.htm |
| 2020-08-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920017565/0001437749-20-017565-index.htm |
| 2020-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920017837/0001437749-20-017837-index.htm |
| 2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/810509/000143774920018032/0001437749-20-018032-index.htm |
| 2020-08-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920018137/0001437749-20-018137-index.htm |
| 2020-08-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920018294/0001437749-20-018294-index.htm |
| 2020-08-25 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/810509/000143774920018666/0001437749-20-018666-index.htm |
| 2020-08-28 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/810509/000143774920018885/0001437749-20-018885-index.htm |
| 2020-09-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920019237/0001437749-20-019237-index.htm |
| 2020-09-02 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/810509/000143774920019241/0001437749-20-019241-index.htm |
| 2020-09-02 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/810509/000143774920019242/0001437749-20-019242-index.htm |
| 2020-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/810509/000143774920019570/0001437749-20-019570-index.htm |
| 2020-09-14 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/810509/000143774920019678/0001437749-20-019678-index.htm |
| 2020-11-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920023028/0001437749-20-023028-index.htm |
| 2020-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000143774920023031/0001437749-20-023031-index.htm |
| 2018-09-24 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000175376318000001/0001753763-18-000001-index.htm |
| 2019-03-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000175376319000001/0001753763-19-000001-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000175376319000002/0001753763-19-000002-index.htm |
| 2019-12-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000175376319000003/0001753763-19-000003-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000175376320000001/0001753763-20-000001-index.htm |
| 2020-09-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/810509/000175376320000002/0001753763-20-000002-index.htm |
| 2017-12-27 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/810509/999999999517003335/9999999995-17-003335-index.htm |
| 2020-01-09 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/810509/999999999520000059/9999999995-20-000059-index.htm |
| 2020-06-23 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/810509/999999999520001509/9999999995-20-001509-index.htm |
| 2020-09-01 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/810509/999999999520002328/9999999995-20-002328-index.htm |
| 2020-09-16 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/810509/999999999520002467/9999999995-20-002467-index.htm |
Navidea Biopharmaceuticals, Inc (NAVB) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Navidea Biopharmaceuticals, Inc (NAVB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 3090%Institutional Ownership: 602%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-02-06 | YEHUDA MICHAEL RICE | Director | Buy | 2,500.00 | 0.00 | 2.50 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774920002034/0001437749-20-002034-index.htm |
| 2019-02-07 | Adam D. Cutler | Director | Buy | 50,000.00 | 0.00 | 50.00 | 100,000.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919002331/0001437749-19-002331-index.htm |
| 2019-02-07 | Claudine Bruck | Director | Buy | 50,000.00 | 0.00 | 50.00 | 100,000.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919002329/0001437749-19-002329-index.htm |
| 2019-02-07 | Sarah Kathryn Rouan | Director | Buy | 50,000.00 | 0.00 | 50.00 | 100,000.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919002338/0001437749-19-002338-index.htm |
| 2018-02-20 | YEHUDA MICHAEL RICE | Director | Buy | 50,000.00 | 0.00 | 50.00 | 100,000.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774918003137/0001437749-18-003137-index.htm |
| 2020-02-06 | Claudine Bruck | Director | Buy | 2,500.00 | 0.00 | 2.50 | 10,050.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774920002027/0001437749-20-002027-index.htm |
| 2020-08-14 | Jed Latkin | CEO, COO & CFO | Buy | 50,000.00 | 0.00 | 50.00 | 107,997.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774920018294/0001437749-20-018294-index.htm |
| 2020-02-06 | Sarah Kathryn Rouan | Director | Buy | 2,500.00 | 0.00 | 2.50 | 10,850.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774920002036/0001437749-20-002036-index.htm |
| 2019-05-16 | Jed Latkin | CEO, COO & CFO | Buy | 1,500.00 | 1.45 | 2,180.40 | 10,950.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919010383/0001437749-19-010383-index.htm |
| 2019-05-17 | Jed Latkin | CEO, COO & CFO | Buy | 1,000.00 | 1.46 | 1,462.90 | 11,950.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919010383/0001437749-19-010383-index.htm |
| 2019-06-05 | Jed Latkin | CEO, COO & CFO | Buy | 1,000.00 | 1.26 | 1,258.30 | 12,950.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919011608/0001437749-19-011608-index.htm |
| 2020-06-02 | Michael Stanley Rosol | Chief Medical Officer | Buy | 6,847.00 | 2.62 | 17,939.14 | 13,097.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774920012481/0001437749-20-012481-index.htm |
| 2019-02-07 | YEHUDA MICHAEL RICE | Director | Buy | 50,000.00 | 0.00 | 50.00 | 150,000.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919002350/0001437749-19-002350-index.htm |
| 2018-02-20 | Mark I Greene | Director | Buy | 50,000.00 | 0.00 | 50.00 | 157,244.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774918003134/0001437749-18-003134-index.htm |
| 2020-02-20 | Jed Latkin | CEO, COO & CFO | Buy | 5,000.00 | 1.08 | 5,400.00 | 17,950.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774920003172/0001437749-20-003172-index.htm |
| 2019-03-22 | John K Jr. Scott | 10% Share Holder | Buy | 357,143.00 | 0.14 | 50,000.02 | 22,261,565.00 | https://www.sec.gov/Archives/edgar/data/810509/000175376319000001/0001753763-19-000001-index.htm |
| 2018-02-20 | Eric K Rowinsky | Director | Buy | 50,000.00 | 0.00 | 50.00 | 341,446.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774918003139/0001437749-18-003139-index.htm |
| 2018-02-20 | Frederick O Cope | SVP & CSO | Buy | 135,694.00 | 0.36 | 48,849.84 | 372,662.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774918003132/0001437749-18-003132-index.htm |
| 2019-01-02 | Adam D. Cutler | Director | Buy | 50,000.00 | 0.00 | 50.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919000184/0001437749-19-000184-index.htm |
| 2018-03-15 | Claudine Bruck | Director | Buy | 50,000.00 | 0.00 | 50.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774918004830/0001437749-18-004830-index.htm |
| 2019-01-02 | Sarah Kathryn Rouan | Director | Buy | 50,000.00 | 0.00 | 50.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919000186/0001437749-19-000186-index.htm |
| 2019-06-18 | John K Jr. Scott | 10% Share Holder | Buy | 4,000,000.00 | 0.75 | 3,000,000.00 | 5,113,078.00 | https://www.sec.gov/Archives/edgar/data/810509/000175376319000002/0001753763-19-000002-index.htm |
| 2019-12-06 | John K Jr. Scott | 10% Share Holder | Buy | 555,555.00 | 0.90 | 499,999.50 | 5,668,633.00 | https://www.sec.gov/Archives/edgar/data/810509/000175376319000003/0001753763-19-000003-index.htm |
| 2020-06-02 | Jed Latkin | CEO, COO & CFO | Buy | 33,997.00 | 2.62 | 89,072.14 | 57,997.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774920012480/0001437749-20-012480-index.htm |
| 2018-06-29 | Frederick O Cope | SVP & CSO | Buy | 212,390.00 | 0.23 | 48,849.70 | 585,052.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774918013286/0001437749-18-013286-index.htm |
| 2019-05-13 | Jed Latkin | CEO, COO & CFO | Buy | 2,400.00 | 1.91 | 4,594.56 | 6,450.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919010054/0001437749-19-010054-index.htm |
| 2020-02-06 | Adam D. Cutler | Director | Buy | 2,500.00 | 0.00 | 2.50 | 7,500.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774920002030/0001437749-20-002030-index.htm |
| 2019-05-13 | Claudine Bruck | Director | Buy | 2,550.00 | 1.90 | 4,855.20 | 7,550.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919010057/0001437749-19-010057-index.htm |
| 2020-02-13 | John K Jr. Scott | 10% Share Holder | Buy | 2,373,529.00 | 0.85 | 2,017,499.65 | 8,042,162.00 | https://www.sec.gov/Archives/edgar/data/810509/000175376320000001/0001753763-20-000001-index.htm |
| 2020-08-30 | John K Jr. Scott | 10% Share Holder | Buy | 5,000.00 | 5.00 | 25,000.00 | 8,047,162.00 | https://www.sec.gov/Archives/edgar/data/810509/000175376320000002/0001753763-20-000002-index.htm |
| 2019-05-17 | Sarah Kathryn Rouan | Director | Buy | 3,350.00 | 1.46 | 4,904.40 | 8,350.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919010580/0001437749-19-010580-index.htm |
| 2019-05-14 | Jed Latkin | CEO, COO & CFO | Buy | 2,000.00 | 1.84 | 3,679.20 | 8,450.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919010054/0001437749-19-010054-index.htm |
| 2019-05-15 | Jed Latkin | CEO, COO & CFO | Buy | 1,000.00 | 1.45 | 1,447.70 | 9,450.00 | https://www.sec.gov/Archives/edgar/data/810509/000143774919010054/0001437749-19-010054-index.htm |